CERC-611 (LY3130481)
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Pipeline Type
New Drugs in Development
Phase Of Development
Preclinical
Sponsors and Collaborators
Cerecor
Mechanism of Action
Glutamate
Mechanism Description
Modulate AMPA Receptors (AMPA antagonist)
Populations Tested In
Focal Seizures
Other Resources
Special FDA Designation
Nonprofit or Government Support
N/A
Nonprofit or Government Support Description
N/A
Previous Presentations
Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
N/A
Location of Clinical Trials
N/A
Clinical Trial link